Soluble mediators of diabetic macular edema: The diagnostic role of aqueous VEGF and cytokine levels in diabetic macular edema

Current Diabetes Reports

Volumn 13, Issue 4, 2013, Pages 476-480

  Owen, Leah A ^a   Hartnett, M Elizabeth ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; Diabetes mellitus; Diabetic retinopathy; Macular edema; VEGF

Indexed keywords

BEVACIZUMAB; CYTOKINE; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; RANIBIZUMAB; STEROID; TRIAMCINOLONE; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ARTICLE; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; CELL INFILTRATION; DIABETIC MACULAR EDEMA; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; INNATE IMMUNITY; LASER COAGULATION; MACROPHAGE; MOLECULAR MECHANICS; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STEROID THERAPY; VISUAL IMPAIRMENT;

CYTOKINES; DIABETIC RETINOPATHY; HUMANS; MACULAR EDEMA; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84880132281     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-013-0382-z     Document Type: Article

References (37)

1. Porta M, Bandello F. Diabetic retinopathy. A Clinical update. Diabetologia. 2002;45:1617-34.
2. Klein R, Klein B, Moss S, Cruickshanks K. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XV. The long term incidence. Ophthalmology. 1995;102:7-16.
3. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic Macular Edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54:1-32.
4. Antonetti D, Klein R, Gardner T. Diabetic retinopathy. N Engl J Med. 2012;366:1227-39.
5. Early Treatment Diabetic Retinopathy Study Group. Photocoagulation for DME: early treatment diabetic retinopathy study report number 1. Arch Ophthalmol. 1985;103:1796-806.
6. Wilson DJ, Finkelstein D, Quigley HA, Green WR. Macular grid photocoagulation. An experimental study on the primate retina. Arch Ophthalmol. 1988;106:100-5.
7. Arevalo J, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, et al. Primary intravitreal bevacizumab for diabetic macular edema: results from the Pan-American collaborative retina study group at 6 month follow-up. Ophthalmology. 2007;114:743-50.
8. Grover D, Li TJ, Chong CC. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2008;1:CD005656.
9. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci. 1995;108:2369-79.
10. Roh MI, Kim HS, Song JH, Lim JB, Kwon OW. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema. Ophthalmology. 2009;116:80-6.
11. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002;133:70-7.
12. Hartnett ME, Tinkham N, Paynter L, Geisen P, Rosenberg P, Koch G, et al. Aqueous VEGF as a predictor of macular thickening following cataract surgery in patients with Diabetes Mellitus. Am J Ophthalmol. 2009;148:895-901.
13. • Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do Dv, et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146-51. This study was one of the first to demonstrate the efficacy of anti-VEGF treatment for DME.
14. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399-405.
15. •• Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. RISE and RIDE Research Group Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789-801. This study demonstrated definitive efficacy of ranibizumab for treatment of DME.
16. •• Diabetic Retinopathy Clinical Research Network, [583 collaborators]. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064-77. This study demonstrated efficacy for both intravitreal steroid and anti-VEGF in treatment of DME.
17. • Funk M, Schmidinger G, Maar N, Bolz M, Benesch T, Zlabinger GJ, et al. Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab. Retina. 2010;30:1412-9. These data demonstrated that while bevacizumab decreased aqueous VEGF to sub-physiologic levels this did not completely reverse DME. Furthermore this study demonstrated the important correlations between cytokine levels and presence of DME.
18. Tesch GH. Role of macrophages in complications of type 2 diabetes. Clin Exp Pharmacol Physiol. 2007;34:1016-9.
19. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol. 2001;132:425-7.
20. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920-7.
21. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol. 2005;140:695-702.
22. Lam DS, Chan CK, Mohamed S, Lai TY, Lee VY, Liu DT, et al. Intravitreal triamcinolone plus sequential sequential grid laser vs triamcinolone or laser alone for treating diabetic macular edema: 6-month outcomes. Ophthalmology. 2007;114:2162-7.
23. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115:1447-9.
24. Funatsu H, Yamashita H, Ideda T, Mimura T, Equchi S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003;110:1690-6.
25. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmology. 2000;133:70-7.
26. Funatsu H, Yamashita H, Noma H, Shimizu E, Mimura T, Hori S. Prediction of macular edema exacerbation after phacoemulsification in patients with nonproliferative diabetic retinopathy. J Cataract Refract Surg. 2002;28:1355-63.
27. •• Oh I, Kim S, Oh J, Lee TS, Huh K. Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy. Current Eye Research. 2010;35:1116-27. These data were important to demonstrate a correlation between elevated aqueous IL-6 and severity of DME.
28. Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacuzumab. Retina. 2006;26:262-9.
29. Funatsu H, Noma H, Mimura T, Equchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116:73-9.
30. •• Sohn HJ, Han DH, Kim IT, Oh IK, Kim KH, Lee DY, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone vs bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011;152:686-94. These data demonstrated that some aqueous cytokine levels appear to be reduced by intravitreal steroid while others do not.
31. Yoshida A, Yoshida S, Khalil AK, Ishibashi T, Inomata H. Role of NF-kB-mediated interleukin-8 expression in intraocular neovascularization. Invest Ophthalmol Vis Sci. 1998;39:1097-106.
32. • Lee WJ, Kang MH, Seong M, Cho HY. Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion. Br J Ophthalmol. 2012;0:1-5. These data were important to show that elevation of aqueous IL-8 is specific for macular edema specifically in the setting of diabetes.
33. Paone A, Galli R, Gabellini C, Lukashev D, Starace D, Gorlach A, et al. Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alpha. Neoplasia. 2010;12:539-49.
34. Hong KH, Ryu J, Han KH. Monocyte chemoattractant protein-1- inductedangiogeneiss is mediated by vascular endothelial growth factor-A. Blood. 2005;105:1405-7.
35. Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney INT Suppl. 2000;77:S113-9.
36. Verma MJ, Mukaida N, Vollmer-Conna U, Matsushima K, Lloyd A, Wakefield D. Endotoxin induced uveitis is partially inhibited by anti-IL-8 antibody treatment. Invest Ophthalmol Vis Sci. 1999;40:2465-70.
37. Hashida N, Ohguro N, Yamamoto S, Nakagawa Y, Tano Y. Unusual neutrophil infiltration under the soft contact lens in a patient with Behcet's disease. Jpn J Ophthalmol. 2003;47:469-72.